Vimarsana
Biggest News Aggregation in the World

Page 9 - Adaptive Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adaptive Research Today - Breaking & Trending Today

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update - Vimarsana News

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study - Vimarsana News

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

By pausing the REM-001 program, the Company expects to save approximately $3.0 million through 2023.

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study - Vimarsana News

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update - Vimarsana News

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer - Vimarsana News

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...